WELCOME TO JOHNS HOPKINS HEALTH ALERTS!

This free public service from Johns Hopkins Medicine helps keep you up to date on the latest breakthroughs for the most common medical conditions which prevent healthy aging. Browse all the articles via the Health Alert Topics navigation bar on the right, or read the headlines below.


Get the latest news sent straight to your Inbox. Register now for your FREE Johns Hopkins Health Alerts. Check the boxes below for all the topics you are interested in, enter your email address, and click "Send." It's fast, easy, and FREE.   Benefits of Being A Registered User

Enter your email here: (Example: yourname@domain.com)
Please send my alerts as:

We value your privacy and will never rent your email address.Already a Member? Manage your Health Alerts


Johns Hopkins Health Alert

Pristiq: A New SNRI for Depression

Comments (1)

Dr. Karen L. Swartz, Director of the Johns Hopkins Mood Disorders Center, answers a reader’s question about the therapeutic benefits of Pristiq, a new antidepressant: I am currently on Effexor (venlafaxine), which has a similar generic name, so I'm wondering how Pristiq differs from Effexor and other SNRIs? Chester, VT

Dr. Swartz: Pristiq (desvenlafaxine succinate) is an antidepressant in the serotonin and norepinephrine reuptake inhibtor (SNRI) class of drugs. Pristiq is indeed very closely related to Effexor (venlafaxine hydrochloride) chemically. In fact, it is metabolic byproduct of Effexor. Pristiq, like Effexor XR, is dosed once daily.

 

What is reported to be different about Pristiq is that the antidepressant medication can be started at a dose high enough to potentially be therapeutic. One of the great challenges with antidepressants is that, for almost all of them, they need to be started at low doses and slowly increased to a potentially therapeutic dose. Since it is impossible to predict which antidepressant will be effective for a given person, the time spent adjusting the dose can be very frustrating, especially if the antidepressant dose not eventually help.

 

For Pristiq, it is recommended to start with a dose of 50 mg daily, which is also typical maintenance dosage. This guideline is based on two things: data showing inconsistent improvement with dosage increments and the finding that patients are generally able to tolerate 50 mg daily as a starting dose.

Pristiq has been shown to be safe at higher doses, but a decision to increase dosage should be made in collaboration with the your psychiatrist and/or primary care physician.

Pristiq, Effexor, and other SNRI's such as Cymbalta have not proven markedly different in their effectiveness. (For that matter, there is not strong evidence that any particular antidepressant or class of antidepressants is superior to another for everyone.) For this reason, if someone is doing well on Effexor, it would be wise to consider staying on that medication rather than switching to another SNRI, including Pristiq.

Posted in Depression and Anxiety on August 19, 2009
Reviewed January 2011


Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Johns Hopkins Health Alerts Disclaimer


Notify Me

Would you like us to inform you when we post new Depression and Anxiety Health Alerts?

Post a Comment

Comments

Health Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the Johns Hopkins editors cannot be answered in this space.

The views expressed here do not constitute medical advice, and do not represent the position of Johns Hopkins Medicine or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.


I have been taking Pristiq to manage hot flashes which has been fairly effective. I also have dysthymia so it serves both purposes. What I want to know is, what others have experienced in relation to weight gain/loss. I have not gained weight but have been trying to lose weight since April and have been unable. I have also been on Wellbutrin for the last 10 years but have stopped that in the last month and am wondering if that could be the reason I am not losing weight.

Posted by: markegard | August 22, 2009 5:00 PM

Post a Comment


Already a subscriber?

Login

Forgot your password?

New to Johns Hopkins Health Alerts?

Register to submit your comments.

(example: yourname@domain.com)

(800) 829-0422

Registered Users Log-in:

Forgot Password?

Become a Registered User!
It's fast and FREE!
The Benefits of Being a Registered User

Health Topic Pages

  • Health Alert
  • Special Report

What is this?

XML


Managing Bipolar Disorder

If you or a loved one has bipolar disorder, you know first-hand what it’s like to live with the ups and downs of this serious mood disorder. The good news is that when properly diagnosed it can be managed effectively with medications and other therapies. That’s why Karen Swartz, M.D and a team of world-famous psychiatrists at Johns Hopkins have gathered together to write Managing Bipolar Disorder. Managing Bipolar Disorder provides the latest thinking on the causes of bipolar disorder and the full range of your treatment options -- including medications and electroconvulsive therapy. This authoritative 70-page special report contains current information you won’t find in any other single source. Read more or order Managing Bipolar Disorder Digital Report




Johns Hopkins White Papers

The 2011 Johns Hopkins White Papers

Depression and Anxiety White Paper— Mood Disorders, Bipolar Disorder (Manic Depression), Phobias, more.

Read More or Order.



The Johns Hopkins Medical Letter: Health After 50

Since 1988, Hopkins experts have been reporting on the latest cutting edge information on treating the major medical conditions affecting the over 50s. Women's health, men's medical concerns, nutrition, weight control, breakthroughs on diabetes, and more, mailed directly to you every month from our specialists.

Read more, or order now and receive two FREE Special Reports...